Xenon phase 3 epilepsy readout 'blows away' expectations, stock soars
Fuente:
FierceBiotech
Xenon Pharmaceuticals’ anti-seizure candidate has smashed a pivotal trial out of the park, lowering seizure rates by more than 50% for some patients.